Pharmaceuticals

A Right Pain in the Peripheries? The Supreme Court Decision in Warner-Lambert v Generics & Actavis

Summary In a significant judgment, the UK Supreme Court has rejected Warner-Lambert’s appeal against the revocation of patent EP(UK) No. 0934061, for the use of pregabalin in the treatment of pain. A key part of the ruling was the upholding of the appeal decision that a higher threshold of plausibility...

Read more

Wisdom of the crowd: how to make sure IP doesn’t derail your crowdfunding efforts

Startups raising hundreds of thousands – even millions – of pounds via Kickstarter may be rarer than it once was, but crowdfunding remains a popular method of fundraising. There are a myriad of options, whether you go down the equity crowdfunding route offered by the likes of Seedrs, CrowdCube, and...

Read more

AI-generated in silico data in patent applications

The impact of AI-generated in silico data on pharma patent applications In silico data generated using AI platforms can identify existing medication candidates and match them with diseases and conditions that do not yet have a cure much quicker and more reliably than a human will ever be able to do. However, it...

Read more

Patent licensing trends in the UK pharmaceutical sector

2018 was billed by some in the industry as the year of pharma M&As. However, as of September, we still haven’t seen the acquisition values that were expected following a rather barren 2017. What we have seen are record high patent licensing deals. If your company is built on a...

Read more

M&A Deals and the Pharmaceutical sector: Are your IP ducks in a row?

2018 has so far been a productive year for M&A deals in the pharmaceutical sector. At the start of the year, Celgene acquired both Impact Biomedicines for around $7 billion and Juno Therapeutics, Inc for a total of approximately $9 billion. In March, Sanofi completed its $11.6 billion acquisition of Bioveratis....

Read more